Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of cerebrovascular and aging-related degenerative diseases.

Methods of preparing red blood cell mimetics and functionalized red blood cell mimetics, and methods of making and using those mimetics, are provided.

The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor.

New aminooxylipids of general formula I, wherein n.sub.1=5-30 and X is polymethylene linker of the general formula II where n.sub.2=2-10, or X is polyethylene glycol linker of the general formula III, wherein n.sub.3=1-14 are provided. A method of preparation of the aminooxylipids of general formula I characterized in that the acylation of N-tert-butoxycarbonyl-polymethylenediamine {(CH.sub.3).sub.3C—O—(C═O)—HN—(CH.sub.2).sub.n—NH.sub.2, n=2-13}, or N-tert-butoxycarbonyl-polyethyleglycoldiamine {(CH.sub.3).sub.3C—O—(C═O)—HN—(CH.sub.2).sub.2—[O—(CH.sub.2)].sub.n—O—(CH.sub.2).sub.2NH.sub.2, n=1-14} with in position C(2) symmetrically branched fatty acids of general formula IV, wherein n.sub.1=5-30, in the presence of condensation reagent, or from acid of general formula IV derived acylchloride of general formula V wherein n.sub.1=5-30, produces N-Boc-aminolipids of general formula VI, wherein n.sub.1=5-30 a X is polymethylene linker of the general formula II or X is polyethylene glycol linker of the general formula III.

Compositions comprising a red blood cell (RBC) having non-toxically coupled thereto a nanoparticle having a low shear modulus or low Young's modulus of less than 10 MPa and containing a drug are provided. In one embodiment, the nanoparticles are optionally coated with protein. In another embodiment, the nanoparticle has no cell-specific targeting moiety or tissue-specific targeting moiety or organ-specific targeting moiety associated therewith. Methods of delivering selected drugs to target organs use these compositions both in vivo and ex vivo treatment of disease and for imaging.

The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

The present invention concerns a short Interfering RNA, which is variant C1858T PTPN22 short interfering RNA duplexes (siRNA), and uses thereof in medical field in the prevention and treatment of autoimmune diseases.

The disclosure relates generally to gamma polyglutamated lometrexol compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated lometrexol, and methods of making and using the gamma polyglutamated lometrexol compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).

Cancer treatment and imaging methods using thermotherapy and drug delivery are disclosed herein. In one embodiment, the method comprises the steps of administering a plurality of antibody or aptamer-conjugated nanoparticles, liposomes, and/or micelles containing a medication and/or gene to a patient in need thereof so as to target a tumor in the patient, at least some of the antibody or aptamer-conjugated nanoparticles, liposomes, and/or micelles attaching to surface antigens of tumor cells of the tumor so as to form a tumor cell/nanoparticle/liposome/micelle complex; and heating the antibody or aptamer-conjugated nanoparticles, liposomes, and/or micelles using an energy source so as to raise the temperature of the tumor cell/nanoparticle complex, micelle complex, and/or liposome complex, thereby releasing one or more medications from the antibody or aptamer-conjugated nanoparticles, liposomes, and/or micelles, and damaging one or more tumor cell membranes at the tumor site.